Executive Board Member. Luke has an extensive scientific background and over 25 years of successful early phase drug development experience delivering pivotal registration studies. He has specialized in the design and delivery of cell therapies, targeted small molecules, immune-oncology clinical development plans across rare indications, solid tumor and hematological malignancies. He also brings strategic operational expertise as well as a consultative approach in developing novel solutions as a subject matter expert in clinical development strategy. Luke holds a Neuro & Molecular Pharmacology Master’s degree and authored a number of publications with a focus on cell signaling pathways at the University Bristol.Prior to joining Lambda & Novum, Luke has held multiple leadership positions in large and mid-size CROs such as IQVIA, PPD and, more recently was the head of oncology business unit at Premier Research. Throughout his career, he successfully worked with a number of small and large biopharma companies